Maternal Fetal Monitoring

LifeWave Biomedical’s first products are intrapartum and antepartum maternal fetal monitors which are designed to lower the cost of care and improve outcomes for all patient populations.


Intrapartum Monitoring

LifeWave Biomedical’s first product is a wireless intrapartum electronic fetal monitor that has design goals of: 1) lowering cost of care to help U.S. healthcare institutions meet their cost reduction goals, 2) improving the experience of labor and childbirth, and 3) improving upon delivery outcomes. The monitor is wireless and is expected to improve upon signal accuracy and reliability in the majority of expectant mothers as compared to existing non-invasive monitors. While it will be used with all expectant mothers, it will provide the greatest value to mothers deemed to be higher risk particularly – the overweight/obese, preterm pregnancies, and multiple gestations. The current care standard for fetal monitoring is a wired Doppler ultrasound device and Toco sensor that are used to assess fetal distress in virtually all first world countries. The LifeWave FetalConnect® solution is expected to improve the experience of labor and improve upon outcomes and lower cost of care. A new solution is demanded as the current care standard is increasingly ineffective with higher risk populations, notably the overweight/obese.

Antepartum Monitoring

The antepartum FetalConnect® product is truly groundbreaking in that it will enable a woman in the third trimester to monitor her fetus at any time, even while remote from a care facility. The solution is initially targeted at higher risk woman but can be utilized by any woman requiring assurance of fetal well-being. It is important to note that fetal monitoring of this kind is more useful for reassurance that the fetus is not in distress. Virtually all pregnant women will likely value a fetal well-being assurance monitor that they could deploy at any time when necessary.

High-risk pregnancies now comprise approximately 30% of all pregnancies in the U.S. This patient population often require “Non-Stress Tests” (NSTs) that sometimes necessitate daily visits to a clinic or hospital for fetal heart and contraction assessment, for the purpose of assessing the presence of fetal distress. Both patients and clinicians alike will welcome a remote solution to the hospital or clinic based NST.

View the California HealthCare Foundation endorsement.